Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Pfizer CEO Albert Bourla told investors he dined with RFK Jr, a vaccine skeptic and nominee to head HHS. They discussed ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback